Gilead Company Profile

✉ Email this page to a colleague

GILEAD has thirty approved drugs.

There are eighty-six US patents protecting GILEAD drugs.

There are two thousand three hundred and thirty-nine patent family members on GILEAD drugs in sixty-six countries and three hundred and ninety-seven supplementary protection certificates in nineteen countries.

International Patents:	2339
US Patents:	86
Tradenames:	24
Ingredients:	24
NDAs:	30
Patent Litigation for Gilead:	See patent lawsuits for Gilead
PTAB Cases with Gilead as patent owner:	See PTAB cases with Gilead as patent owner

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-001	Feb 7, 2018		RX	Yes	Yes	9,732,092	⤷ Sign Up	Y	Y		⤷ Sign Up
Gilead Sciences Inc	VEKLURY	remdesivir	POWDER;INTRAVENOUS	214787-001	Oct 22, 2020		RX	Yes	Yes		⤷ Sign Up				⤷ Sign Up
Gilead Sciences Inc	SUNLENCA	lenacapavir sodium	SOLUTION;SUBCUTANEOUS	215973-001	Dec 22, 2022		RX	Yes	Yes	9,951,043	⤷ Sign Up	Y	Y		⤷ Sign Up
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-001	Feb 7, 2018		RX	Yes	Yes	11,744,802	⤷ Sign Up	Y			⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Gilead Sciences Inc	COMPLERA	emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate	TABLET;ORAL	202123-001	Aug 10, 2011	6,043,230*PED	⤷ Sign Up
Gilead	LETAIRIS	ambrisentan	TABLET;ORAL	022081-001	Jun 15, 2007	RE42462	⤷ Sign Up
Gilead	TRUVADA	emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	021752-001	Aug 2, 2004	6,043,230*PED	⤷ Sign Up
Gilead	LETAIRIS	ambrisentan	TABLET;ORAL	022081-002	Jun 15, 2007	RE42462	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	150 mg, 200 mg, and 250 mg	➤ Subscribe	2012-05-17
➤ Subscribe	Tablets	150 mg, 150 mg, 200 mg, 300 mg	➤ Subscribe	2018-10-04
➤ Subscribe	Capsules	200 mg	➤ Subscribe	2012-07-16
➤ Subscribe	Tablets	5 mg and 10 mg	➤ Subscribe	2015-02-09
➤ Subscribe	Tablets	100 mg/150 mg, 133 mg/200 mg, and 167 mg/250 mg	➤ Subscribe	2017-05-19
➤ Subscribe	Tablets	300 mg	➤ Subscribe	2010-01-26
➤ Subscribe	Tablets	200 mg/25 mg/300 mg	➤ Subscribe	2015-05-20
➤ Subscribe	Tablets	150 mg	➤ Subscribe	2015-12-09
➤ Subscribe	Tablets	10 mg	➤ Subscribe	2010-06-08
➤ Subscribe	Tablets	200 mg/300 mg	➤ Subscribe	2008-09-26
➤ Subscribe	Tablets	600 mg/200 mg/300 mg	➤ Subscribe	2008-12-29

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1663240	2015/054	Ireland	⤷ Sign Up	PRODUCT NAME: A COMBINATION OF RILPIVIRINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING THE HYDROCHLORIDE SALT, AND TENOFOVIR, IN PARTICULAR TENOFOVIR DISOPROXIL FUMARATE; REGISTRATION NO/DATE: EU/1/11/737/001-002 20111128
2101777	122016000039	Germany	⤷ Sign Up	PRODUCT NAME: AMBRISENTAN IN VERWENDUNG IN DER KOMBINATIONSTHERAPIE MIT TADALAFIL; REGISTRATION NO/DATE: EU/1/08/451 20151120
2487163	C20170001 00217	Estonia	⤷ Sign Up	PRODUCT NAME: ATASANAVIIR/KOBITSISTAAT;REG NO/DATE: EU/1/15/1025 15.07.2015
1663240	2015/053	Ireland	⤷ Sign Up	PRODUCT NAME: A COMBINATION OF RILPIVIRINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING THE HYDROCHLORIDE SALT, TENOFOVIR, IN PARTICULAR TENOFOVIR DISOPROXIL FUMARATE, AND EMTRICITABINE; REGISTRATION NO/DATE: EU/1/11/737/001-002 20111128
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.